---
title: Neoadjuvant Immunochemotherapy vs Chemoradiotherapy in ESCC
nct_id: NCT07236320
overall_status: COMPLETED
phase: NA
sponsor: Yongtao Han
study_type: INTERVENTIONAL
primary_condition: Esophageal Squamous Cell Carcinoma (ESCC)
countries: China
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT07236320.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT07236320"
ct_last_update_post_date: 2025-11-19
last_seen_at: "2026-05-12T06:56:08.985Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# Neoadjuvant Immunochemotherapy vs Chemoradiotherapy in ESCC

**Official Title:** Neoadjuvant Immunochemotherapy Versus Chemoradiotherapy in Locally Advanced Esophageal Cancer: A Real-World Study

**NCT ID:** [NCT07236320](https://clinicaltrials.gov/study/NCT07236320)

## Key Facts

- **Status:** COMPLETED
- **Phase:** NA
- **Study Type:** INTERVENTIONAL
- **Target Enrollment:** 200
- **Lead Sponsor:** Yongtao Han
- **Conditions:** Esophageal Squamous Cell Carcinoma (ESCC)
- **Start Date:** 2018-03-01
- **Completion Date:** 2025-02-28
- **CT.gov Last Update:** 2025-11-19

## Brief Summary

This retrospective real-world study aimed to compare neoadjuvant immunochemotherapy (NICT) and neoadjuvant chemoradiotherapy (NCRT) followed by esophagectomy in patients with locally advanced esophageal squamous cell carcinoma (ESCC). A total of 203 consecutive patients treated at Sichuan Cancer Hospital between March 2018 and March 2022 were analyzed (NICT: 59; NCRT: 144). The primary endpoints were overall survival (OS) and disease-free survival (DFS); secondary endpoints included pathological complete response (pCR), tumor regression grade (TRG), and R0 resection rate. After inverse probability of treatment weighting adjustment, baseline characteristics were balanced between groups. Both groups achieved comparable long-term OS and DFS, while NCRT showed higher rates of local pathological response. Exploratory subgroup analysis suggested that patients achieving pCR after NICT might have superior survival outcomes. The study indicates that NICT provides similar long-term survival compared to NCRT and may offer immunologic advantages for selected responders, warranting further validation in prospective multicenter trials.

## Eligibility

- **Minimum age:** 18 Years
- **Maximum age:** 80 Years
- **Sex:** ALL
- **Healthy Volunteers:** No

```
Inclusion Criteria:

* Age 18-80 years
* Histologically confirmed thoracic ESCC
* Clinical stage cT1N+M0 or cT2-4aN0-3M0
* Received neoadjuvant therapy (immunochemotherapy or chemoradiotherapy) followed by esophagectomy

Exclusion Criteria:

* History of other malignancies
* Did not complete neoadjuvant therapy or required salvage surgery
* Incomplete baseline or follow-up data
```

## Arms

- **NICT group** (EXPERIMENTAL)
- **NCRT group** (ACTIVE_COMPARATOR)

## Interventions

- **Neoadjuvant immunochemotherapy** (DRUG) — NACI group patients received treatment of minimally 2 cycles of ICIs agent (mainly camrelizumab or toripalimab, 200 mg every 3 weeks (200 mg every 3 weeks)) combined with concurrent chemotherapy.
- **Neoadjuvant Chemoradiotherapy** (DRUG) — NCRT group patients followed the concurrent NCRT treatment, and the total neoadjuvant radiotherapy dose was 40.0-50.4Gy with 1.8-2.14 Gy fractions and 5 fractions/week.

## Primary Outcomes

- **Overall Survival (OS)** _(time frame: 5 years)_ — Time from first treatment to death from any cause or last follow-up.
- **Disease-Free Survival (DFS)** _(time frame: 5 years)_ — Time from surgery to recurrence, death, or last follow-up.

## Secondary Outcomes

- **Pathological Complete Response (pCR) rate** _(time frame: 3 months)_
- **Tumor Regression Grade (TRG)** _(time frame: 3 months)_
- **R0 resection rate** _(time frame: 3 months)_

## Locations (1)

- Sichuan Cancer Hospital and Institute, Chengdu, Sichuan, China

## Recent Field Changes (last 30 days)

- `outcomes.secondary` — added _(2026-05-12)_
- `armsInterventions.arms` — added _(2026-05-12)_
- `armsInterventions.interventions` — added _(2026-05-12)_
- `status.overallStatus` — added _(2026-05-12)_
- `status.primaryCompletionDate` — added _(2026-05-12)_
- `status.completionDate` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.phases` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.minAge` — added _(2026-05-12)_
- `eligibility.maxAge` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `outcomes.primary` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_
- `locations.sichuan cancer hospital and institute|chengdu|sichuan|china` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT07236320.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT07236320*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*